Annual Reports

Quarterly Reports


  • 8-K (Oct 14, 2011)
  • 8-K (Oct 11, 2011)
  • 8-K (Sep 30, 2011)
  • 8-K (Sep 26, 2011)
  • 8-K (Aug 22, 2011)
  • 8-K (Aug 2, 2011)


Cephalon 8-K 2011

Documents found in this filing:

  1. 8-K
  2. Ex-99.1
  3. Ex-99.1











Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of report (Date of earliest event reported) October 11, 2011 (October 7, 2011)


Cephalon, Inc.

(Exact Name of Registrant as Specified in Charter)







(State or Other Jurisdiction




(IRS Employer

of Incorporation)


File Number)


Identification No.)


41 Moores Road
Frazer, Pennsylvania



(Address of Principal Executive Offices)


(Zip Code)


Registrant’s telephone number, including area code (610) 344-0200


Not Applicable

(Former Name or Former Address, if Changed Since Last Report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 8.01               Other Information.


On October 7, 2011, Cephalon, Inc. (the “Company”) and Teva Pharmaceutical Industries Ltd. (“Teva”) issued a press release announcing that the U.S. Federal Trade Commission has accepted the proposed consent order in connection with the pending acquisition of the Company by Teva and granted early termination of the Hart Scott Rodino waiting period.  The Company hereby incorporates by reference the press release dated October 7, 2011, attached hereto as Exhibit 99.1 and made a part of this Item 8.01.


Item 9.01               Financial Statements and Exhibits.


(d)                                             Exhibits.


Exhibit No.


Description of Exhibit






Press Release of Cephalon, Inc. and Teva Pharmaceutical Industries Ltd. dated October 7, 2011






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.









Date: October 11, 2011


/s/ Gerald J. Pappert



Gerald J. Pappert



Executive Vice President, General Counsel and Secretary






Exhibit No.


Description of Exhibit






Press Release of Cephalon, Inc. and Teva Pharmaceutical Industries Ltd. dated October 7, 2011



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki